JAMP-TOBRAMYCIN 40 MG
TOBRAMYCIN (TOBRAMYCIN SULFATE) : 40 MG · DIN 02420287 · JAMP PHARMA CORPORATION
Health Canada status: CANCELLED POST MARKET
What is JAMP-TOBRAMYCIN?
JAMP-TOBRAMYCIN 40 MG contains TOBRAMYCIN (TOBRAMYCIN SULFATE) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02420287, held by JAMP PHARMA CORPORATION, supplied as SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 15-Nov-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP-TOBRAMYCIN used for?
Tobramycin Injection, USP may be indicated for the treatment of the following infections when caused by susceptible organisms: septicemia, complicated and recurrent urinary tract infections, lower respiratory infections, serious skin and soft tissue infections including burns and peritonitis and central nervous system infections caused by organisms resistant to antibiotics usually considered efficacious in these infections. Tobramycin is usually active against most strains of the following organisms in vitro and in clinical infections: Pseudomonas aeruginosa, Proteus sp. (indole-positive and indole-negative), including Proteus mirabilis; Morganella morganii, Providencia rettgeri, and Proteus vulgaris. Escherichia coli, Klebsiella-Enterobacter-Serratia group, Citrobacter sp., Providencia sp., Staphylococci, including Staphylococcus aureus (coagulase-positive and coagulase-negative).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02420287 |
|---|---|
| Brand name | JAMP-TOBRAMYCIN |
| Generic / active ingredient | TOBRAMYCIN (TOBRAMYCIN SULFATE) : 40 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 40 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01GB01 TOBRAMYCIN |
| AHFS class | 08:12.02 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 15-Nov-2022 |
| Original market date | 2014-03-11 00:00:00 |
How is it administered?
Adults: 3 mg/kg/day in 3 equal doses. Life-threatening: up to 5 mg/kg/day. Children: 6-7.5 mg/kg/day in 3-4 doses. Administer by IM injection or IV infusion (20-60 mins). Adjust for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15°C – 30°C [see USP Controlled Room Temperature]
How is it supplied?
2 mL, boxes of 10, and of 30 mL, boxes of 1 multidose glass vials
Contraindications
Known hypersensitivity to tobramycin or any other aminoglycoside.
Warnings and precautions
Potential for ototoxicity (vestibular/auditory) and nephrotoxicity. Monitor renal and eighth-nerve function. Contains sodium bisulfite (allergic risk). Clostridium difficile-associated disease.
Is TOBRAMYCIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01GB01 TOBRAMYCIN. 9 of 23 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TEVA-TOBRAMYCIN | 60 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02389622 |
| TOBI | 300 MG / 5 ML | SOLUTION | BGP PHARMA ULC | MARKETED | DIN 02239630 |
| TOBI PODHALER | 28 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 02365154 |
| TOBRAMYCIN FOR INJECTION | 1.2 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 00533688 |
| TOBRAMYCIN INJECTION | 40 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02230640 |
| TOBRAMYCIN INJECTION USP | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02241209 |
| TOBRAMYCIN INJECTION USP | 40 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02502372 |
| TOBRAMYCIN INJECTION USP | 40 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02533103 |
| TOBRAMYCIN INJECTION USP | 40 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02241210 |
| AJ-TOBRAMYCIN | 40 MG | LIQUID | AGILA JAMP CANADA INC | CANCELLED PRE MARKET | DIN 02384930 |
Who else supplies TOBRAMYCIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TOBRAMYCIN appears in 85 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.